Table 1 |
|||||||
|
Immunomodulatory Glucan Extracts: Oral Animal Studies |
|||||||
|
Source |
Extract |
Animal |
Dose/day |
Duration of study |
Treatment |
Effects |
Reference |
|
|
|||||||
|
Agaricus (A. blazei) subrufescens |
α-1,6 and α-1,4 glucans |
8-week ♀ C3H/He mice (5/group) |
100 mg/kg IG every 3 days |
1 month |
Healthy animals |
↑ #s splenic T lymphocytes (Thy1.2, CD4+ and CD8+) |
[24] |
|
|
|
||||||
|
Aqueous |
7-9-week ♂ Balb/cByJ mice (40/group) |
1 ml 0.45N, 0.6N, or 3N aqueous extract |
2 months |
All doses ↑ serum IgG levels, CD3+ T cell populations and PML phagocytic activity |
[22] |
||
|
|
|||||||
|
7-9-week male Balb/cByJ mice (40/group) |
1 ml 0.45N, 0.6N, or 3N aqueous extract |
10 weeks |
IP injection of OVA at 4 weeks |
0.6N and 3N ↑ levels of OVA-specific serum IgG 28 days post-immunization; all doses ↑ delayed-type hypersensitivity and TNF-α secreted from splenocytes at 10 weeks; 0.6N ↑ splenocyte proliferation at 10 weeks |
|||
|
|
|||||||
|
5-6 -week ♀ BALB/cHsdOla mice (8/group × 2) |
One 200 μl extract day 1, orogastric intubation |
1 week |
Injected IP fecal solution day 2 |
↓ CFU in blood of mice with severe peritonitis & improved overall survival rate in all peritonitis groups |
[46] |
||
|
|
|||||||
|
6-week BALB/c nu/nu mice (7/group) |
2.5 mg extract days 20-41, drinking water |
41 days |
Injected SC Sp-2 myeloma cells day 1 |
↓ tumor size & weight after 21 days treatment |
[65] |
||
|
|
|||||||
|
Aqueous, acid treated |
6-week ♀ C57BL/6 mice (10/group) |
20, 100 or 500 μg/ml, drinking water |
9 days |
Injected IP human ovarian cancer cells day 1 |
500 μg/ml ↓ tumor weight |
[66] |
|
|
|
|||||||
|
20, 100 or 500 μg/ml, drinking water |
3 weeks |
Injected IV murine lung cancer (3LL) cells |
100 & 500 μg/ml ↓ #s metastatic tumors |
||||
|
|
|||||||
|
Aqueous, with 200 ng/day β-glucan |
6-week ♀ BALB/c mice (10/group) |
200 ng days 5-21 |
3 weeks |
Injected Meth A tumor cells day 1 |
↓ tumor size & weight |
[23] |
|
|
|
|||||||
|
2 weeks |
Injected Meth A tumor cells |
↑ cytotoxic T lymphocyte activity & spleen cell IFN-α protein |
|||||
|
|
|||||||
|
300 mg |
5 days |
Healthy animals |
↑ splenic NK cell activity |
||||
|
|
|||||||
|
Avena spp. |
β-glucans (particulate) |
6-7 -week ♀ C57BL/6 mice (7/group) |
3 mg every 48 h, days 1-3 |
1 month |
Oral E. vermiformis oocytes day 10 |
↓ E. vermiformis fecal oocyte #s; increased intestinal anti-merozoite IgA; ↓ # of IL-4-secreting MLN cells |
[42] |
|
|
|||||||
|
3 mg on alternating days, days 1-10 |
22 days |
Injected IP Eimeria vermiformis day 10 |
↓ E. vermiformis fecal oocyte #s; ↑ anti-merozoite intestinal IgA |
[43] |
|||
|
|
|||||||
|
β-glucans (soluble) |
4-week ♂ CD-1 mice (24/group) |
0.6 mg/ml 68% β-glucan, drinking water |
1 month |
Resting or exercise-stressed (days 8-10) animals administered HSV-1 IN day 10 |
↓ morbidity in resting and exercise-stressed animals; ↓ mortality in exercise-stressed animals; pre-infection, ↑ Mø anti-viral resistance in resting and exercise-stressed animals |
[38] |
|
|
|
|
||||||
|
~3.5 mg days 1-10, drinking water |
Resting or exercise-stressed (days 5-10) animals administered HSV-1 IN day 10 |
Pre-infection, ↑ Mø antiviral resistance in resting animals |
[41] |
||||
|
|
|||||||
|
4-week ♂ CD-1 mice (10/group) |
0.6 mg/ml 68% β-glucan, drinking water |
10 days |
Resting animals or animals exposed to a bout of fatiguing exercise days 8-10 or moderate exercise days 5-10, injected IP with thioglycollate on day 10 |
↑ neutrophil mobilization in resting & moderately exercised animals; ↑ neutrophil respiratory burst activity in resting and fatiguing exercised animals |
[37] |
||
|
|
|||||||
|
4-week ♂ CD-1 mice (19-30/group) |
0.8 mg/ml 50% β-glucan, days 1-10, drinking water |
1 month |
Resting or exercise-stressed (days 8-10) animals administered IN clodronate-filled liposomes to deplete Mø days 8 & 14 & infected IN with HSV-1 day 10 |
↓ morbidity, mortality, symptom severity in exercise-stressed animals, without Mø depletion |
[40] |
||
|
|
|
||||||
|
4-week ♂ CD-1 mice (20/group) |
Resting or exercise-stressed (days 8-10) animals administered HSV-1 IN day 10 |
↓ morbidity in exercise-stressed & resting animals; ↓ mortality in exercise-stressed animals |
[39] |
||||
|
|
|||||||
|
Ganoderma lucidum |
Aqueous |
7-week ♂ CD-1 mice (26/group) |
5% of diet |
5 months |
Injected IM DMH once a week, weeks 1-10 |
↓ aberrant crypt foci per colon, tumor size, cell proliferation, nuclear staining of β-catenin |
[69] |
|
|
|||||||
|
4-8-week BALB/c mice (10/group) |
50, 100 or 200 mg/kg, oral |
10 days |
Injected SD Sarcoma 180 cells |
↓ of tumor weight was dose dependent: 27.7, 55.8, 66.7%, respectively |
[67] |
||
|
|
|||||||
|
Ganoderma lucidum (mycelia) |
Aqueous |
7-week ♂ F344/Du Crj rats (16/group) |
1.25% or 2.5% of diet |
6 months |
Injected SC AOM once a week, weeks2-5 |
Both doses ↓ colonic adenocarcinoma incidence; 2.5% ↓ total tumor incidence; both doses ↓ nuclear staining of β-catenin and cell proliferation |
[68] |
|
|
|||||||
|
Ganoderma tsugae |
Aqueous |
8-week ♀ BALB/cByJNarl mice (14/group) |
0.2-0.4% of diet (young fungi); 0.33 or 0.66% of diet (mature fungi) |
5 weeks |
Injected IP OVA days 7, 14, 21; aerosolized OVA twice during week 4 |
In splenocytes, both doses of both extracts ↑ IL-2 and IL-2/IL-4 ratios, 0.2% young extract and 0.66% mature extract ↓ IL-4; in Mø, 0.66% mature extract ↑ IL-1β, both doses of both extracts ↑ IL-6 |
[53] |
|
|
|||||||
|
Grifola frondosa |
D fraction |
Mice: 1) ICR, 2) C3H/HeN, 3) CDF1 (10/group) |
1.5 mg every other day, beginning day 2 |
13 days |
Implanted SC: 1) Sarcoma-180, 2) MM-46 carcinoma, or 3) IMC carcinoma cells |
↓ tumor weight & tumor growth rate: 1) 58%, 2) 64%, and 3) 75%, respectively |
[71] |
|
|
|||||||
|
5-week ♂ BALB/c mice (10/group) |
2 mg, days 15-30 |
45 days |
Injected in the back with 3-MCA, day 1 |
↓ (62.5%) # of animals with tumors; ↑ H202 production by plasma Mø; ↑ cytotoxic T cell activity |
[72] |
||
|
|
|||||||
|
Hordeum vulgare |
β-1,3;1,4 or β-1,3;1,6-D-glucans |
Athymic nu/nu mice (4-12/group) |
40 or 400 μg IG for 4 weeks |
31 weeks |
Mice with human xenografts (SKMel28 melanoma, A431 epidermoid carcinoma, BT474 breast carcinoma, Daudi lymphoma, or LAN-1 neuroblastoma) ± mAb (R24, 528, Herceptin, Rituximab, or 3F8, respectively) therapy twice weekly |
400 μg + mAb ↓ tumor growth & ↑ survival; higher MW ↓ tumor growth rate for both doses |
[75] |
|
|
|||||||
|
β-1,3;1,4-D-glucans |
Athymic BALB/c mice |
4, 40, or 400 μg for 3-4 weeks |
1 month |
Mice with neuroblastoma (NMB7, LAN-1, or SK-N-ER) xenografts, ± 3F8 mAb therapy twice weekly |
40 and 400 μg doses + mAB ↓ tumor growth; 400 μg dose ↑ survival. Serum NK cells required for effects on tumor size |
[76] |
|
|
|
|||||||
|
C57BL/6 WT and CR3-deficient mice (10/group) |
0.4 mg for 3 weeks |
100 days |
Injected SC RMA-S-MUC1 lymphoma cells day 1 ± IV 14.G2a or anti-MUC1 mAb every 3rd day |
±mAB ↓ tumor diameter; ↑ survival |
[73] |
||
|
|
|||||||
|
β-glucans |
♀ Fox Chase ICR immune-deficient (SCID) mice (9/group) |
400 μg days 1-29 |
50 days |
Mice with human (Daudi, EBV-BLCL, Hs445, or RPMI6666) lymphoma xenografts, ± Rituximab mAb therapy twice weekly |
+mAB ↓ tumor growth and ↑ survival |
[74] |
|
|
|
|||||||
|
Laminaria digitata |
Laminarin |
♂ ICR/HSD mice (3/group) |
1 mg |
1 day |
Healthy animals |
↑ Mø expression of Dectin-1 in GALT cells; ↑ TLR2 expression in Peyer's patch dendritic cells |
[29] |
|
|
|||||||
|
♂ Wistar rats (7/group) |
5% of diet days 1-4, 10% of diet days 5-25 |
26 days |
Injected IP E. coli LPS day 25 |
↓ liver ALT, AST, and LDH enzyme levels; ↑ ED2-positive cells, .↓ peroxidase-positive cells in liver; ↓ serum monocytes, TNF-α, PGE2, NO2 |
[44] |
||
|
|
|||||||
|
Lentinula edodes |
SME |
6-week nude mice |
0.1 ml water with10% SME/10 g body weight days 1-19, 33-50 |
50 days |
Injected SC prostate cancer (PC-3) cells day 1 |
↓ tumor size |
[80] |
|
|
|||||||
|
β-glucans |
♀ 3- and 8-week BALB/c mice (15/group) |
50, 100 or 250 μg |
1-2 weeks |
Healthy animals |
250 μg dose ↑ spleen cell IL-2 secretion |
[27] |
|
|
|
|||||||
|
♀ 3- and 8-week BALB/c mice (15/group) |
50, 100 or 250 μg |
1-2 weeks |
Injected murine mammary carcinoma (Ptas64) cells into mammary fat pads 2 weeks before treatment |
↓ tumor weight |
|||
|
|
|||||||
|
Lentinan |
6-week ♂ Wistar-Imamichi specific-pathogen free rats (10/group) |
1 mg twice weekly |
1-2 months |
Healthy animals |
↑ T cell #s, helper-cell #s & helper/suppressor ratio, ↓ suppressor cell level at 4, but not 8 weeks |
[26] |
|
|
|
|||||||
|
5-6-week ♂ pre-leukemic AKR mice (10/group) |
3 mg, days 1-7 |
3 weeks |
Injected SC K36 murine lymphoma cells day 7 |
↓ tumor weight; ↑ tumor inhibition rate (94%) |
[82] |
||
|
|
|
||||||
|
5-6-week athymic mice (10/group) |
5 weeks |
Injected SC colon cancer (LoVo and SW48, SW480 and SW620, or SW403 and SW1116) cells day 7 |
↓ tumor weight, ↑ tumor inhibition rate (>90%) |
||||
|
|
|||||||
|
♂ AKR mice |
3 mg |
1 day |
Pre-leukemic mice |
↑ serum IFN-α and TNF-α, peak at 4 h and then back to normal at 24 h; ↑ IL-2 and IL-1α, peak at 2 h and back to normal at 24 h; ↑ CD3+ T, CD4+ T, CD8+ T, B lymphocytes |
[81] |
||
|
|
|||||||
|
Phellinus linteus |
Aqueous, alcohol-precipitated |
6-7-week C57BL/6 mice (10-50/group) |
200 mg/kg in drinking water |
1 month |
Healthy animals |
↑ production and secretion of IFN-γ by con A stimulated T cells |
[32] |
|
|
|||||||
|
Saccharomyces cerevisiae |
Scleroglucan |
♂ ICR/HSD mice (3/group) |
1 mg one day before challenge (day 1) |
6 days |
IV Staphylococcus aureus or Candida albicans day 2 |
↑ long-term survival |
[29] |
|
|
|||||||
|
β-1,3;1,6 glucans (particulate) |
3 and 8-week ♀ BALB/c mice (15/group) |
50, 100 or 250 μg |
1-2 weeks |
Injected murine mammary carcinoma (Ptas64) cells into mammary fat pads 2 weeks before treatment |
↓ tumor weight |
[27] |
|
|
|
|
||||||
|
β-1,3-glucan |
Healthy animals |
All 3 doses ↑ phagocytic activity of blood monocytes & neutrophils & ↑ spleen cell IL-2 secretion |
|||||
|
|
|||||||
|
WT or CCD11b-/- C57BL/6 mice (2/group) |
0.4 mg for 3 weeks |
100 days |
Injected SC RMA-S-MUC1 lymphoma cells ± 14.G2a or anti-MUC1 mAb IV injection every 3rd day |
↓ tumor diameter when included with mAb; ↑ survival with and without mAb |
[73] |
||
|
|
|||||||
|
C57BL/6mice (4/group) |
25 mg |
1 week |
Healthy animals |
↑ # intestinal IELs; ↑ # TCRαβ+, TCR γδ+, CD8+, CD4+, CD8αα+, CD8αβ+ T cells in IELs; ↑ IFN-γ mRNA expression in IELs and spleen |
[28] |
||
|
|
|||||||
|
Sclerotinia sclerotiorum |
SSG |
6-8-week specific pathogen-free ♂ CDF1 mice (3/group) |
40 or 80 mg/kg days 1-10 |
2 weeks |
Healthy animals |
10 mg dose ↑ acid phosphatase activity of peritoneal Mø (day 14) |
[30] |
|
|
|||||||
|
40, 80 or 160 mg/kg days 2-6 |
35 days |
Implanted SC Metha A fibrosarcoma cells day 1 |
80 mg dose ↓ tumor weight |
||||
|
|
|
||||||
|
6-8-week specific pathogen-free ♂ CDF1 mice (10/group) |
40, 80 or 160 mg/kg days 2-11 |
Injected ID IMC carcinoma cells day 1 |
|||||
|
|
|||||||
|
6-8-week specific-pathogen free ♂ mice of BDF1 and C57BL/6 mice (7/group) |
0.5, 1, 2, or 4 mg days 1-10 |
2-3 weeks |
Injected IV Lewis lung carcinoma (3LL) cells |
2 mg ↓ # of 3LL surface lung nodules at 2 weeks |
[83] |
||
|
|
|||||||
|
Sclerotium rofsii |
Glucan phosphate |
♂ ICR/HSD mice (3/group) |
1 mg |
1 day |
Healthy animals |
↑ systemic IL-6; ↑ Mø expression of Dectin-1 in GALT cells; ↑ TLR2 expression in dendritic cells from Peyer's patches |
[29] |
|
|
|||||||
|
Trametes (Coriolus) versicolor |
PSP |
6-8-week ♂ BALB/c mice (10/group) |
35 μg days 5-29 in drinking water |
29 days |
Implanted SC Sarcoma-180 cells day 1 |
↓ tumor growth & vascular density |
[94] |
|
|
|||||||
|
Ramberg et al. Nutrition Journal 2010 9:54 doi:10.1186/1475-2891-9-54 |
|||||||